Total revenues were up 42% to $151 million, and earnings were at $57 million ($0.65 a share), up 85% over the third quarter of last year. For the first nine months of the year, earnings have been a staggering $3.58 per share, but a large chunk of that does include milestone payments from Bristol-Myers Squibb (NYSE:BMY).